New research published February 3, 2026, reveals a key mutation in the Ebola virus that significantly increased its infectiousness during the 2018-2020 outbreak in the Democratic Republic of Congo, which remains a public health concern in the region [[3]]. Scientists with Sun Yat-sen university in China identified the variant, dubbed GP-V75A, as a driver of the outbreak’s intensity and a potential threat to existing treatments. The findings underscore the critical need for real-time genomic surveillance to track viral evolution and guide effective responses to future outbreaks of this deadly disease, which can be difficult to distinguish from other infectious illnesses [[1]].
Researchers in China have identified a key mutation in the Ebola virus that significantly boosted its ability to infect cells during a major outbreak, offering new insights into disease monitoring and drug development.
The research, published in the journal Cell, was led by Professor Qian Jun of Sun Yat-sen University, in collaboration with researchers from Guangzhou Eighth People’s Hospital of Guangzhou Medical University, Jilin University First Hospital, and other teams at Sun Yat-sen University. The team shared their findings with Xinhua News Agency on February 3, 2026.
The study focused on the Ebola outbreak in the Democratic Republic of Congo from 2018 to 2020, the second-largest outbreak in history, which infected more than 3,000 people and resulted in over 2,000 deaths. Understanding how viruses evolve during outbreaks is crucial for effective public health responses.
Researchers sought to determine whether the virus itself evolved to prolong the outbreak, alongside the challenges posed by local healthcare systems.
In 2022, the team analyzed 480 complete Ebola virus genomes and discovered a variant carrying a specific mutation in the viral glycoprotein, named GP-V75A. This variant emerged early in the outbreak in the Democratic Republic of Congo and quickly replaced the original strain. Its increasing prevalence coincided with a significant rise in infection numbers, suggesting it conferred a transmission advantage, according to the research team.
Further experiments using various models confirmed the biological effects of the mutation. The results showed that GP-V75A markedly enhanced the virus’s ability to infect multiple types of host cells and mice.
The research also revealed potential clinical concerns. The GP-V75A mutation appeared to reduce the effectiveness of some existing therapeutic antibodies and small-molecule entry inhibitors, indicating a potential risk of drug resistance.
“The research tells us that during the emergence of major infectious disease outbreaks, real-time genomic surveillance and evolutionary analysis of the pathogen are crucial,” said Qian. “This can not only warn of changes in viral transmission risks but also proactively assess the effectiveness of existing drugs and vaccines, guiding us to adjust control strategies accordingly.”
The team emphasized the importance of continuous viral genome monitoring during outbreaks to anticipate evolutionary threats and inform the development of broad-spectrum countermeasures. The research paper, titled “Molecular characterization of the Ebola virus glycoprotein V75A replacement in the 2018-2020 epidemic,” is currently available online.
